domingo, 2 de febrero de 2014

Identification, Evaluation, and Treatment of Pati... [ISRN Oncol. 2013] - PubMed - NCBI

Identification, Evaluation, and Treatment of Pati... [ISRN Oncol. 2013] - PubMed - NCBI



 2013 Dec 22;2013:260847. eCollection 2013.

Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States.

Abstract

Recognizing the importance of identifying patients at high risk for inherited cancer predisposition, the United States Preventive Services Task Force (USPSTF) has outlined specific family history patterns associated with an increased risk for BRCA mutations. However, national data indicate a need to facilitate the ability of primary care providers to appropriately identify high risk patients. Once a patient is identified as high risk, it is necessary for the patient to undergo a detailed genetics evaluation to generate a differential diagnosis, determine a cost-effective genetic testing strategy, and interpret results of testing. With identification of inherited predisposition, risk management strategies in line with national guidelines can be implemented to improve patient outcomes through cancer risk reduction and early detection. As use of genetic testing increasingly impacts patient outcomes, the role of primary care providers in the identification and care of individuals at high risk for hereditary cancer becomes even more important. Nevertheless it should be acknowledged that primary care providers face many competing demands and challenges to identify high risk patients. Therefore initiatives which promote multidisciplinary and coordinated care, potentially through academic-community partnerships, may provide an opportunity to enhance care of these patients.

PMID:
 
24455306
 
[PubMed - as supplied by publisher] 
PMCID:
 
PMC3884954
 
Free PMC Article

No hay comentarios:

Publicar un comentario